Insulin aspart with niacinamide (Fiasp) is now approved for use in pediatric (children) with diabetes. Niacinamide allows for faster absorption of insulin aspart. Fiasp was approved in 2017, and expanded to use in insulin pumps in 2019. Excited to have another rapid acting insulin analog options for children. To learn more, please click below.
Please share your thoughts and subscribe to receive my blogs.
#children #diabetes #insulin #Fiasp
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.